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OBJECTIVE—To characterize differences in whole-body glu-
cose metabolism between commonly used inbred mouse strains.
RESEARCH DESIGN AND METHODS—Hyperinsulinemic-eu-
glycemic (8.5 mmol/l) and -hypoglycemic (3.0 mmol/l) clamps
were done in catheterized, 5-h-fasted mice to assess insulin
action and hypoglycemic counter-regulatory responsiveness. Hy-
perglycemic clamps (15 mmol/l) were done to assess insulin
secretion and compared with results in perifused islets.
RESULTS—Insulin action and hypoglycemic counter-regulatory
and insulin secretory phenotypes varied considerably in four
inbred mouse strains. In vivo insulin secretion was greatest in
129X1/Sv mice, but the counter-regulatory response to hypogly-
cemia was blunted. FVB/N mice in vivo showed no increase in
glucose-stimulated insulin secretion, relative hepatic insulin re-
sistance, and the highest counter-regulatory response to hypo-
glycemia. In DBA/2 mice, insulin action was lowest among the
strains, and islets isolated had the greatest glucose-stimulated
insulin secretion in vitro. In C57BL/6 mice, in vivo physiological
responses to hyperinsulinemia at euglycemia and hypoglycemia
were intermediate relative to other strains. Insulin secretion by
C57BL/6 mice was similar to that in other strains in contrast to
the blunted glucose-stimulated insulin secretion from isolated
islets.
CONCLUSIONS—Strain-dependent differences exist in four in-
bred mouse strains frequently used for genetic manipulation and
study of glucose metabolism. These results are important for
selecting inbred mice to study glucose metabolism and for
interpreting and designing experiments. Diabetes 57:1790–
1799, 2008
T
he development of new mouse models has al-
lowed investigators to address questions related
to glucose metabolism in ways that were not
previously possible. Use of inbred mouse strains
and proliferation of techniques to produce genetic modi-
ﬁcations have been invaluable in deﬁning the role of select
genes under physiological conditions. To rigorously exam-
ine complex physiological processes in vivo has required
the development of new experimental approaches for the
mouse and the adaptation of techniques previously used in
larger animals. Important technical advancements, includ-
ing surgical catheterization (1) and miniaturization of
clamp techniques (2) for the mouse, have furthered our
ability to dissect the physiology underlying insulin action,
insulin secretion, and counter-regulation to insulin-in-
duced hypoglycemia under well-controlled physiological
conditions.
Mouse models produced through genetic modiﬁcation
have been generated in a variety of mouse strains. It is
widely recognized that the background mouse strain can
inﬂuence phenotypes. Several examples have been de-
scribed where identical genetic mutations in different
inbred mouse strains result in different phenotypes (3–5).
These ﬁndings indicate that the contribution of the inbred
strain genetic background to the phenotype is an impor-
tant factor to consider when designing and interpreting
experiments.
The goal of the current studies was to deﬁne the
glucoregulatory phenotype of four commonly used inbred
mouse strains under well-controlled conditions. We inves-
tigated insulin action using the hyperinsulinemic-euglyce-
mic clamp, counter-regulatory response during an insulin-
induced hypoglycemic clamp, and insulin secretion during
a hyperglycemic clamp. Insulin secretion assessed in vivo
was compared with insulin secretion in perifused islets.
RESEARCH DESIGN AND METHODS
In vivo mouse procedures. All procedures are standard in the Vanderbilt
Mouse Metabolic Phenotyping Center (MMPC; http://www.mmpc.org) and
were approved by the Vanderbilt Animal Care and Use Committee. Male
C57BL/6, 129X1/Sv, DBA/2, and FVB/N mice (The Jackson Laboratories) were
purchased at 9 weeks of age and studied at 12 weeks of age. Housing was
temperature (23°C) and humidity controlled on a 12-h light:dark schedule with
mice given free access to food (Harlan Teklad LM-485, no. 7912) and water.
Surgical procedures have been described previously (2). Brieﬂy, mice were
anesthetized with sodium pentobarbital, and the carotid artery and jugular
vein were catheterized. Free catheter ends were tunneled under the skin to the
back of the neck, externalized, and sealed with steel plugs. Lines were ﬂushed
daily with 50 l saline containing 200 units/ml heparin and 5 mg/ml
ampicillin. These methods permit arterial sampling from an indwelling cath-
eter and are less stressful than cut-tail sampling (2). Mice (n  98) were
individually housed and recovered for 5 days after surgery. Only mice
returning to within 10% of presurgical body weight were studied. Body
composition was determined 1 day before experimentation using an mq10
NMR analyzer (Bruker Optics).
The arterial catheter was used for blood sampling, and the venous catheter
was used for infusing in all protocols (2,6). Catheters were attached to a
swivel 1 h before the ﬁrst infusion. Mice were unrestrained and not handled
thereafter to minimize stress. The experimental period (t  0–120 min) began
at 1300 h with the infusion of insulin (Humulin R; Eli Lilly) in euglycemic and
hypoglycemic clamps and glucose in hyperglycemic clamps. The steady-state
period was deﬁned by stable glycemia between t  80–120 min. Saline-washed
erythrocytes were infused (5–6 l/min) during the experimental period to
prevent a 5% fall in hematocrit.
Blood samples were collected from the arterial catheter in tubes containing
From the
1Department of Molecular Physiology and Biophysics, Vanderbilt
University School of Medicine, Nashville, Tennessee; the
2Vanderbilt Uni-
versity–NIH Mouse Metabolic Phenotyping Center, Vanderbilt University
School of Medicine, Nashville, Tennessee; the
3Department of Medicine,
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University
School of Medicine, Nashville, Tennessee; the
4Departments of Pharmacol-
ogy and Cancer Biology, Duke University Medical Center, Durham, North
Carolina; the
5VA Tennessee Valley Healthcare System, Nashville, Tennessee.
Corresponding author: Eric Berglund, eric.d.berglund@vanderbilt.edu.
Received 15 November 2007 and accepted 3 April 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 8 April
2008. DOI: 10.2337/db07-1615.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
1790 DIABETES, VOL. 57, JULY 2008EDTA and centrifuged, and plasma was stored at 20°C until analyzed. After
the ﬁnal blood sample in euglycemic clamps, animals were injected with a
bolus of pentobarbital, and liver and gastrocnemius were dissected and frozen
in liquid nitrogen. Blood glucose refers to arterial blood glucose measured
using the glucose oxidase method.
Euglycemic clamp. A primed continuous [3-
3H]glucose infusion (5-Ci bolus
and 0.05 Ci/min) was given at t  120 min to measure glucose turnover.
The clamp was started at t  0 min with a continuous insulin infusion (24
pmol  kg
1  min
1), and the [3-
3H]glucose was increased to 0.1 Ci/min to
minimize changes in speciﬁc activity. Glucose (5 l) was measured every 10
min, and euglycemia (8.5 mmol/l) was maintained using a variable glucose
infusion rate (GIR). Samples (10 l) to determine glucose speciﬁc activity
were taken at t  15 and 5 min and every 10 min from t  80–120 min.
Samples (50 l) were taken to measure plasma insulin at t  0, 100, and 120
min.
Hypoglycemic clamp. At t  0 min, a constant insulin infusion (120 pmol 
kg
1  min
1) was started to induce hypoglycemia, and a variable GIR was
used to maintain blood glucose at 3.0 mmol/l. Blood glucose (5 l) was
measured at t  15, 5, 5, 10, 15, and 20 min and then every 10 min until t 
120 min. Samples (250 l) were taken to measure plasma insulin, glucagon,
corticosterone, and catecholamines at t  15, 30, 60, and 120 min.
Hyperglycemic clamp. At t  0 min, a variable GIR was used to increase and
maintain blood glucose at 15.0 mmol/l. Blood glucose (5 l) was measured
at t  15, 5, 5, 10, 15, and 20 min and then every 10 min until t  120 min.
Samples (50 l) to measure plasma insulin were taken at t  15, 5, 5, 10,
15, and 20 min and then every 20 min until t  120 min. Samples (50 l) to
measure plasma C-peptide were taken at t  5, 15, 110, and 120 min.
Samples (100 l) to measure plasma catecholamines were taken at t  5 and
120 min.
Islet isolation and perifusion. Islets were hand isolated (n  4–6 mice/
strain) as previously described (7,8). After overnight culture, 25 islets per
mouse were perifused with low (5.6 mmol/l) glucose in perifusion media (38.1
mmol/l sodium bicarbonate, 4.0 mmol/l L-glutamine, 1.0 mmol/l sodium
pyruvate, 0.5% phenol red, 5.0 mmol/l HEPES, and 0.1% BSA in 1.0 l Dulbecco’s
modiﬁed Eagle’s medium without glucose [pH 7.4]) for a 30-min period. Islets
were then perifused with 16.7 mmol/l glucose (6 min), 5.6 mmol/l glucose (24
min), 16.7 mmol/l glucose  45 mol/l isobutylmethylxanthine (IBMX) (6
min), 5.6 mmol/l glucose (24 min), and 16.7 mmol/l glucose  125 mol/l
tolbutamide (6 min). Three-minute fractions were collected, and the ﬁve
fractions before glucose stimulation were used to determine baseline insulin
secretion.
Measurement of pancreatic islet mass. Pancreatic insulin content (n 
4–6 mice/strain) was calculated as previously described (9). Three sections
from different regions of the pancreas (n  3–4 mice/strain) were stained for
insulin and glucagon to determine total islet, -cell, and -cell area by
integrated morphometry (9).
Plasma hormones, glucose, and plasma radioactivity. Plasma insulin (10),
glucagon (10), epinephrine (11), norepinephrine (11), and corticosterone (12)
were determined by the Vanderbilt MMPC. Plasma glucose and [3-
3H]glucose
radioactivity was determined as described previously (2).
Immunoblotting. Protein content was determined for GLUT4, hexokinase II
(HKII), total Akt, and Akt phosphorylated on serine 473 (p-Akt) in gastrocne-
mius from euglycemic clamp mice using standard methods. Total Akt and
p-Akt were also measured in liver, and Akt activation was determined by the
p-Akt–to–total Akt ratio. Glyceraldehyde-3-phosphate dehydrogenase was
used as a standard.
Statistical analyses and calculations. Values are represented as means 	
SE. Statistical analyses were conducted using repeated-measures ANOVA or t
tests when appropriate. Statistical signiﬁcance was established at P 
 0.05.
EndoRa and Rd were determined using Steele’s non–steady-state equations
(13). Negative endoRa values were seen in all groups except FVB/N mice and
were treated as such. Speciﬁc activities were constant during euglycemic-
clamp steady state, suggesting that a modeling error would be minor. It is
possible that negative endoRa in a steady state may result from normal
analytical error and/or small variability in glucose infusate. The homeostatic
model assessment of insulin resistance (HOMA-IR) and quantitative insulin
sensitivity check (QUICKI) were calculated using the equations [(G0 
I0)/405)] and [1/log (G0)  log (I0)], where G0 and I0 refer to 5-h fasting plasma
glucose and insulin (14). Disposition index was determined by the equation
disposition index  SIClamp  insulin secreted, where “SIClamp” is insulin
sensitivity during the euglycemic-clamp steady state and “insulin secreted” is
measured during the 120-min hyperglycemic clamp. SIClamp was deﬁned as
M/(G  I) (14), where M is the steady-state GIR, G is steady-state glucose,
and I is the difference between basal and steady-state insulin.
RESULTS
Basal condition. Basal data from 5-h-fasted mice are
shown in Table 1. C57BL/6 mice had the highest blood
glucose and glucagon, whereas 129X1/Sv mice had the
lowest blood glucose and insulin. FVB/N mice had the
TABLE 1
Basal 5-h fasted data
BL6 129 FVB DBA
Body weight (g) 22.1 	 0.3* 21.2 	 0.3† 24.2 	 0.3 22.5 	 0.5
Muscle mass (% body wt) 77 	 1*‡§ 72 	 17 3 	 17 0 	 1
Fat mass (% body wt) 9 	 1*‡§ 13 	 1¶ 14 	 1 18 	 1
Whole-blood glucose (mmol/l) 9.1 	 0.2‡§ 7.1 	 0.2†¶ 9.1 	 0.3 7.8 	 0.2
Plasma glucose (mmol/l) 9.7 	 0.4‡§ 8.6 	 0.3 9.2 	 0.1 8.8 	 0.1
Blood glucose:plasma glucose 0.96 	 0.04‡ 0.84 	 0.01†¶ 0.95 	 0.02 0.90 	 0.02
Insulin (pmol/l) 138 	 24‡§ 90 	 12¶ 114 	 18 198 	 12
C-peptide (nmol/l) 0.59 	 0.06* 0.59 	 0.06† 0.36 	 0.06 0.46 	 0.06
Glucagon (ng/l) 61 	 7*‡ 48 	 3¶ 39 	 36 0 	 6
Corticosterone (ng/l) 0.17 	 0.02 0.23 	 0.04 0.25 	 0.05 0.17 	 0.02
Epinephrine (pmol/l) 300 	 55*‡ 
109†¶ 775 	 175 257 	 44
Norepinephrine (nmol/l) 0.92 	 0.14*§ 0.89 	 0.08†¶ 1.24 	 0.11 1.27 	 0.19
Glucose endoRa (mmol  kg
1  min
1) 0.10 	 0.01 0.10 	 0.01 0.12 	 0.01 0.12 	 0.01
Glucose Rd (mmol  kg
1  min
1) 0.11 	 0.01 0.11 	 0.01 0.12 	 0.01 0.12 	 0.01
Fasting plasma glucose–to–insulin ratio 100 	 11§ 107 	 13¶ 105 	 18 44 	 3.6
HOMA-IR 11.4 	 1.7‡ 4.9 	 0.5†¶ 7.7 	 1.1 11.5 	 0.9
QUICKI 0.47 	 0.02*‡ 0.31 	 0.01 0.30 	 0.01 0.34 	 0.07
Data are means 	 SE. Data from 12-week-old, 5-h-fasted C57BL/6J (BL6), 129X1/SvJ (129), FVB/NJ (FVB), and DBA/2J (DBA) male mice.
Body weight, blood glucose, insulin, fasting glucose–to–insulin ratio, HOMA-IR, and QUICKI were compiled from basal samples during
hyperinsulinemic-euglycemic (euglycemic), insulin-induced hypoglycemic (hypoglycemic), and hyperglycemic clamp experiments in
chronically catheterized, conscious mice (n  27 for BL6; 25 for 129; 22 for FVB; and 24 for DBA mice). QUICKI and HOMA-IR were
calculated using equations described in RESEARCH DESIGN AND METHODS. Epinephrine and norepineprhine were measured before hypoglycemic
and hyperglycemic clamps (n  19 for BL6; 18 for 129; 15 for FVB; and 14 for DBA mice). Muscle mass, fat mass, glucagon, and corticosterone
were measured before hypoglycemic clamps (n  8 for BL6; 7 for 129; 7 for FVB; and 7 for DBA mice). EndoRa, Rd, and plasma glucose were
determined from euglycemic clamp data (n  8 for BL6; 9 for 129; 7 for FVB; and 10 for DBA mice). Comparisons are *BL6 vs. FVB, †129
vs. FVB, ‡BL6 vs. 129, §BL6 vs. DBA, ¶129 vs. DBA, and FVB vs. DBA, where statistical signiﬁcance is established at P 
 0.05.
E.D. BERGLUND AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1791highest epinephrine and lowest glucagon, whereas DBA/2
mice had the highest fat mass and insulin. There were also
strain differences in the ratio of whole-blood glucose to
plasma glucose, suggesting differences in erythrocyte glu-
cose transport kinetics. Basal hematocrit was similar
between strains.
Insulin action. Insulin action was determined from the
response to a constant insulin infusion. The GIR required
to maintain euglycemia was highest in 129X1/Sv mice,
lowest in DBA/2 mice, and similar in FVB/N and C57BL/6
mice (Fig. 1B; Table 2). However, steady-state insulin and
InsulinClamp-Basal was higher in 129X1/Sv (P 
 0.05) and
DBA/2 (P  0.05; NS) mice compared with C57BL/6 and
FVB/N mice (Table 2). When GIR was normalized to
steady-state insulin, insulin action was lower in DBA/2
mice compared with 129X1/Sv, C57BL/6, and FVB/N mice
(Table 2). This relative insulin resistance in DBA/2 mice
was consistent with higher fasting insulin (Table 1).
Hyperinsulinemia fully suppressed endoRa in 129X1/Sv,
C57BL/6, and DBA/2 mice, but endoRa was incompletely
suppressed in FVB/N mice (Table 2). Steady-state Rd was
lowest in DBA/2 mice, intermediate in C57BL/6 mice, and
highest in 129X1/Sv and FVB/N mice (Table 2). Rd normal-
ized to steady-state insulin levels was also lower in DBA/2
mice compared with 129X1/Sv, C57BL/6, and DBA/2 mice,
which is consistent with normalized GIR results (Table 2).
There were no strain-dependent differences in gastroc-
nemius GLUT4 or HKII protein (Fig. 2A and B). Total Akt
was also similar in muscle and liver from each strain.
There were no differences in gastrocnemius Akt activation
(Fig. 2C). However, hepatic Akt activation was lower in
FVB/N mice compared with 129X1/Sv, C57BL/6, and DBA/2
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FIG. 1. Whole-blood glucose (A; mmol/l) and GIR (B; mmol  kg
1  min
1) during 120 min (inset shows glucose AUC [mmol/kg in 120 min]) in
euglycemic-hyperinsulinemic clamp experiments in 5-h-fasted, surgically catheterized C57BL/6 (BL6; n  8), 129X1/Sv (129; n  9), FVB/N (FVB;
n  7), and DBA/2 (DBA; n  10) male mice. A 96 pmol/kg insulin bolus was given at t  0 min followed by a 24 pmol  kg
1  min
1 constant
infusion, and euglycemia (8.5 mmol/l) was maintained during the clamp using a variable GIR. Basal samples were taken at t  15 and 0 min,
and the mean is represented as t  0 min. All values are means  SE, and comparisons are
AC57BL/6 versus 129X1/Sv,
BC57BL/6 versus FVB/N,
CC57BL/6 versus DBA/2,
D129X1/Sv versus FVB/N,
E129X1/Sv versus DBA/2, and
FFVB/N versus DBA/2, where statistical signiﬁcance is established
at P < 0.05 and differences are noted above each time point for clarity.
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1792 DIABETES, VOL. 57, JULY 2008mice (Fig. 2D). This is consistent with incomplete suppres-
sion of endoRa in FVB/N mice.
Hypoglycemic counter-regulation. Steady-state insulin
was elevated to similar levels (1,974 	 120, 2,262 	 270,
2,220 	 162, and 1,962 	 126 pmol/l) in C57BL/6, 129X1/Sv,
FVB/N, and DBA/2 mice, respectively, during hypoglyce-
mic clamps. Steady-state GIR required to maintain hypo-
glycemia was lowest in FVB/N mice compared with similar
rates in 129X1/Sv, C57BL/6, and DBA/2 mice (Fig. 3A and
B). Total glucose requirement was highest in 129X1/Sv
mice compared with C57BL/6, FVB/N, and DBA/2 mice
(Fig. 3B, inset). The glucose requirement was inversely
related to the counter-regulatory response.
In response to hypoglycemia, glucagon increased in
C57BL/6, FVB/N, and DBA/2 mice to 4.0-, 9.9-, and 2.6-fold
above basal and remained elevated (Fig. 3C). Glucagon
was only transiently elevated in 129X1/Sv mice (2.3-fold
above basal). Corticosterone were transiently elevated in
DBA/2 mice but did not increase in C57BL/6, 129X1/Sv, and
FVB/N mice (Fig. 3D). Epinephrine was increased in
C57BL/6, FVB/N, and DBA/2 mice but was below the limits
of detection in 129X1/Sv mice (Fig. 3E). Norepinephrine
was increased in each strain in the hypoglycemic clamp
(Fig. 3F). However, in FVB/N, the increase was no more so
than during the hyperglycemic clamp at t  120 min.
Insulin secretion. Insulin secretion in response to hyper-
glycemia was assessed in vivo and compared with isolated
islets to discern intra-islet mechanisms relative to whole-
body physiology. Blood glucose was increased and main-
tained at 15 mmol/l (Fig. 4A). The GIR was highest in
129X1/Sv mice, intermediate in C57BL/6 and DBA/2 mice,
and lowest in FVB/N mice (Fig. 4B). Insulin was increased
in C57BL/6, 129X1/Sv, and DBA/2 mice but not in FVB/N
mice despite a similar hyperglycemic stimulus (Fig. 4C).
The C-peptide responses paralleled insulin responses (Fig.
4D), and the insulin–to–C-peptide ratio did not differ
between strains or change over time. Clamp norepineph-
rine remained similar to basal levels in C57BL/6, 129X1/Sv,
and DBA/2 mice (0.78 	 0.16, 1.08 	 0.19, and 1.72 	 0.60
nmol/l) but was signiﬁcantly increased in FVB/N mice
(2.86 	 0.58 nmol/l). Epinephrine was unchanged from
basal in C57BL/6 and DBA/2 mice (331 	 38 and 318 	 25
pmol/l), whereas FVB/N levels were increased to 2,038 	
552 pmol/l. Epinephrine was below the limit of detection
in 129X1/Sv mice even during hypoglycemia.
In isolated perifused islets, basal insulin secretion was
0.48 	 0.18, 0.30 	 0.18, 0.42 	 0.06, and 1.20 	 0.60 pmol/
min in C57BL/6, 129X1/Sv, FVB/N, and DBA/2 mice, indi-
cating strain-dependent differences (Fig. 5). Insulin secre-
tory response to perifusion with high glucose, high glucose
 isobutylmethylxanthine, and high glucose  tolbut-
amide was highest in DBA/2 mice compared with other
strains (Fig. 5). Thus, the response to high glucose was
C57BL/6 
 129X1/Sv 
 FVB/N 
 DBA/2. A similar re-
sponse to isobutylmethylxanthine was seen in C57BL/6,
129X1/Sv, and FVB/N mice, whereas the response in
DBA/2 mice was signiﬁcantly higher. The response to
tolbutamide in C57BL/6, 129X1/Sv, FVB/N, and DBA/2
mice was similar to the response to high glucose, suggest-
ing little difference in KATP channel closure or sensitivity
to the drug between strains.
Disposition index. Disposition index is an empirical
measure of glucose tolerance integrating insulin secretion
and insulin sensitivity. Disposition index was calculated
TABLE 2
Hyperinsulinemic-euglycemic clamp data
BL6 129 FVB DBA
GIR (mmol  kg
1  min
1) 0.30 	 0.01* 0.37 	 0.02†‡ 0.32 	 0.02 0.26 	 0.01
Insulin (pmol  l
1) 338 	 29§ 420 	 37 360 	 34¶ 472 	 59
InsulinClamp-Basal (pmol  l
1) 230 	 26 305 	 45† 211 	 17 282 	 47
GIR/insulin (mmol  l
1  
kg  min
1  pmol
1
1)  10
4 9.4 	 0.8§ 9.2 	 0.8† 9.4 	 1.2¶ 6.4 	 0.9
GIR/insulinClamp-Basal (mmol  l
1  
kg  min
1  pmol
1
1)  10
4 14.5 	 1.9 14.9 	 2.6 15.5 	 1.4 15.4 	 4.6
EndoRa (mmol  kg
1  min
1) 0.03 	 0.01 0.03 	 0.02† 0.02 	 0.01¶ 0.02 	 0.01
Rd (mmol  kg
1  min
1) 0.27 	 0.01*§ 0.33 	 0.02‡ 0.34 	 0.02¶ 0.24 	 0.01
Rd/insulin (mmol  L
1  
kg  min
1  pmol
1
1)  10
4 8.4 	 0.7§ 8.3 	 0.7† 10.2 	 0.5¶ 5.5 	 0.8
InsulinClamp-Basal/insulin infusion (kg  min  L
1) 9.6 	 1.1 12.7 	 1.9† 8.8 	 0.7 10.6 	 2.3
Data are means 	 SE. Steady-state data during 120-min hyperinsulinemic-euglycemic clamp experiments (24 pmol  kg
1  min
1 insulin) in
chronically catheterized, conscious, 5-h-fasted C57BL/6 (BL6; n  8), 129X1/Sv (129; n  9), FVB/N (FVB; n  7), and DBA/2 (DBA; n  10)
male 12 week-old mice. EndoRa and Rd are determined as described in RESEARCH DESIGN AND METHODS. Insulin Clamp-Basal/insulin infusion is an
assessment of insulin clearance. Steady-state values are the mean of ﬁve samples taken every 10 min from t  80–120 min. Comparisons are
*BL6 vs. 129, †129 vs. FVB, ‡129 vs. DBA, §BL6 vs. DBA, ¶FVB vs. DBA, and BL6 vs. FVB, where statistical signiﬁcance is established at P 

0.05.
TABLE 3
Pancreatic islet mass in four mouse strains
BL6 129 FVB DBA
Pancreatic insulin content (nmol/g pancreas) 25.8 	 3.1*† 10.2 	 1.4‡ 17.2 	 0.9‡ 13.7 	 1.2
Insulin content in isolated islets (pmol/islet equivalent) 10.6 	 0.5*† 7.9 	 0.6‡ 11.9 	 0.3‡ 7.9 	 0.3
Total islet mass (mg) 2.5 	 0.3 1.8 	 0.1 2.8 	 0.4 3.4 	 0.2
-Cell mass (mg) 2.3 	 0.3 1.5 	 0.1 2.6 	 0.4 3.0 	 0.2
-Cell mass (mg) 0.20 	 0.04 0.23 	 0.03 0.18 	 0.03 0.38 	 0.05
Data are means 	 SE. Total pancreatic insulin content, islet insulin content in isolated islets (normalized for size 
islet equivalent), total islet
mass, -cell mass, and -cell mass from 12-week-old male C57BL/6 (BL6), 129X1/Sv (129), FVB/N (FVB), and DBA/2 (DBA) mice (n  4–6
mice/group). Comparisons are *BL6 vs. 129, †BL6 vs. FVB, ‡129 vs. DBA, and §FVB vs. DBA, where statistical signiﬁcance is established at
P 
 0.05.
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DIABETES, VOL. 57, JULY 2008 1793by combining insulin sensitivity (SI) data from euglycemic
clamps and insulin secretion data (insulin area under the
curve [AUC]) from hyperglycemic clamps. Disposition
index values were 1.28 	 0.03, 2.07 	 0.16, 0.06 	 0.01, and
0.24 	 0.02 in C57BL/6, 129X1/Sv, FVB/N, and DBA/2 mice,
respectively, indicating that FVB/N mice had the lowest
capacity to dispose of glucose.
DISCUSSION
The goal in this study was to systematically analyze
glucose metabolism in four representative inbred mouse
strains using three clamp techniques to study in vivo
physiology under well-controlled conditions. In C57BL/6,
129X1/Sv, FVB/N, and DBA/2 mice, we show strain-depen-
dent differences in insulin action, hypoglycemic counter-
regulation, and insulin secretion. These four strains were
selected for comparison based on recommendations of the
National MMPC Steering Committee because these strains
are frequently used in metabolic studies. In these experi-
ments, glucoregulatory phenotype was assessed using in
vivo euglycemic, hypoglycemic, and hyperglycemic
clamps developed to study whole-body physiology in
mice. This research emphasizes that genetic back-
ground is a critical factor to consider when designing
and interpreting experiments. These results are impor-
tant because in vivo clamp techniques are increasingly
used to study physiology in mice, and this is the ﬁrst
published study to comprehensively address the contri-
bution of genetic background to results obtained during
in vivo clamp experiments.
While a number of previous studies have investigated
phenotypic glucoregulatory differences between different
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FIG. 2. Comparison of Glut4 (A), HKII (B), and p-Akt/total Akt (Akt) protein content in gastrocnemius muscle (C) and liver (D) tissue from
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Comparisons are
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E129X1/Sv versus DBA/2, where statistical signiﬁcance is established at
P < 0.05.
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1794 DIABETES, VOL. 57, JULY 2008inbred strains (3–5,15–23), a key distinction in these
studies is that techniques to study physiology in con-
scious, unstressed mice under well-controlled glycemic
conditions were used. One previously published study
used in vivo clamp techniques to examine differences
between two different inbred mouse strains (4). This study
assessed insulin action using methods (i.e., cut-tail blood
sampling, large insulin prime, and overnight fast) previ-
ously shown to induce acute hepatic insulin resistance and
higher catecholamines (2).
The majority of previous studies performed in vivo to
study whole-body physiology have used insulin and glu-
cose tolerance tests to study glucose metabolism (5,15,18–
20). These assessments can be difﬁcult to interpret
because results are generally expressed as percent change
relative to basal blood glucose or insulin levels, which may
vary by strain or with genetic manipulation. Clamp meth-
ods are considered the gold standard for assessing glucose
metabolism because glycemia is controlled, thus alleviat-
ing interpretation problems related to changes in blood
glucose.
Euglycemic clamp results indicate strain-dependent dif-
ferences in insulin action and highlight complexities of
this method. GIR levels were different between strains,
suggesting differences in insulin action, but steady-state
insulin varied between strains. Normalizing GIR to clamp
insulin accounts for differences and permits a more com-
plete interpretation of insulin action. GIR normalized to
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FIG. 3. Data from 120-min insulin-induced hypoglycemic clamp experiments in 5-h-fasted, surgically catheterized C57BL/6 (BL6; n  8), 129X1/Sv
(129; n  9), FVB/N (FVB; n  9), and DBA/2 (DBA; n  10) male mice. Insulin was infused at t  0 min at 120 pmol  kg
1  min
1, and whole-blood
glucose (A; mmol  l
1) was maintained at 3.0 using a variable GIR (B; mmol  kg
1  min
1). Inset in B depicts the glucose AUC during the 120-min
experimental period determined by the trapezoidal method. The hypoglycemic counter-regulatory response was assessed by determining glucagon
(C; ng/l), corticosterone (D; ng/l), epinephrine (F; pmol/l), and norepinephrine (G; nmol/l) at t  0 (basal), 30, 60, and 120 min. Epinephrine levels
in 129X1/Sv mice were below detection at all time points and were excluded from F. All values are means  SE, and comparisons are
AC57BL/6
versus 129X1/Sv,
BC57BL/6 versus FVB/N,
CC57BL/6 versus DBA/2,
D129X1/Sv versus FVB/N,
E129X1/Sv versus DBA/2, and
FFVB/N versus DBA/2,
where statistical signiﬁcance is established at P < 0.05 and differences are noted above each time point for clarity.
E.D. BERGLUND AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1795insulin indicates that DBA/2 mice are insulin resistant
compared with 129X1/Sv, C57BL/6, and FVB/N mice. This
is consistent with higher basal insulin in DBA/2 mice,
which may reﬂect some degree of -cell compensation.
There were no strain-dependent differences in GIR nor-
malized to InsulinClamp-Basal (Table 2). The larger Insu-
linClamp-Basal in 129X1/Sv mice compared with FVB/N mice
suggests strain-dependent differences in insulin clearance.
One might also speculate that differences in clamp insulin
are due to insulin-mediated suppression of -cell insulin
secretion. It is common not to report insulin levels (24–
26). The present study demonstrates that insulin must be
reported to fully interpret results from clamp studies.
Insulin clamp GIR and Rd were signiﬁcantly correlated
with QUICKI and HOMA-IR (P 
 0.01). The correlation
coefﬁcients comparing GIR to QUICKI and HOMA-IR were
0.53 and 0.54, respectively. The correlation coefﬁcients
comparing Rd to QUICKI and HOMA-IR were 0.53 and
0.50, respectively. These correlations were equally sig-
niﬁcant using GIR and Rd normalized to insulin compared
with QUICKI and HOMA-IR.
Euglycemic clamp studies also suggest tissue-speciﬁc
differences in insulin action. Rd was lower in DBA/2 mice
compared with other strains. The lower Rd in DBA/2 mice
did not correspond with differences in GLUT4 or HKII
protein content or Akt activation in skeletal muscle. Lower
Rd in DBA/2 mice did correspond to a higher fat mass,
which is consistent with an inverse relationship between
fat mass and peripheral insulin action. This relationship
also exists in humans. It is likely that the higher fat mass
in DBA/2 mice contributes to insulin resistance, but it is
impossible to establish a causal relationship from these
studies. Hyperinsulinemia did not fully suppress endoRa in
FVB/N mice, indicating relative hepatic resistance to insu-
lin. This corresponded with a lower activation of hepatic
Akt. The insulin infusion used here was not ideal for
resolving liver phenotypes because the dose was beyond
the most sensitive region of insulin to endoRa dose-
response curve (2). This was evident by negative endoRa
values in all but FVB/N mice. An insulin dose 
15 pmol 
kg
1  min
1 would better isolate hepatic insulin action
phenotypes.
The results also indicate that the response to hypogly-
cemia is strain dependent. The hypoglycemic clamp, to our
knowledge, had only been done in C57BL/6 mice (12,27).
Our results indicate that the endocrine response is largely
absent in 129X1/Sv mice compared with C57BL/6, FVB/N,
and DBA/2 mice. In contrast, the endocrine response in
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FIG. 4. Data from 120-min hyperglycemic clamp experiments in 5-h-fasted, surgically catheterized C57BL/6 (BL6; n  8), 129X1/Sv (129; n  9),
FVB/N (FVB; n  9), and DBA/2 (DBA; n  10) male mice. Whole-blood glucose (A; mmol/l) levels were elevated and maintained at 15 mmol/l using
a variable GIR (B; mmol  kg
1  min
1). C: Insulin (pmol/l) secretion was assessed at t  5, 10, 15, 20, and then every 20 min from t  40–120
min (inset shows insulin secretion AUC [pmol/l in 120 min]). D: C-peptide (nmol/l) was assessed at t  100 and 120 min. Basal values (t  0 min)
represent the mean of two samples taken at t  15 and 5 min. All values are means  SE, and comparisons are
AC57BL/6 versus 129X1/Sv,
BC57BL/6 versus FVB/N,
CC57BL/6 versus DBA/2,
D129X1/Sv versus FVB/N,
E129X1/Sv versus DBA/2, and
FFVB/N versus DBA/2, where statistical
signiﬁcance is established at P < 0.05 and differences are noted above and below each time point for clarity.
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strains. This marked endocrine response in FVB/N mice
did not correspond with lower GIR (compared with
C57BL/6 and DBA/2) during the hypoglycemic clamp. This
could be due to different sensitivities to glucagon and/or
catecholamines, but it is more likely due to high insulin
levels, which may mask the effects of counter-regulatory
hormones. These ﬁndings are not only critical factors for
hypoglycemic clamps but are also important issues in
insulin tolerance tests used to estimate insulin action. The
key metric in both is the insulin-induced fall in glucose.
Insulin tolerance tests could be complicated by differences
in basal glycemia or differences in the counter-regulatory
response when comparing mixed-background mice or
different strains.
The insulin secretory response to hyperglycemia further
highlights phenotypic differences between strains and the
complexity underlying the physiology of insulin secretion.
Several groups have previously investigated differences in
insulin secretion in vitro and in vivo using glucose toler-
ance tests in inbred mouse strains (15,19,20,22,23). Our
measurements made in vivo using hyperglycemic clamps
extend these results to ﬁxed glycemic conditions. The
objective was to match blood glucose between strains and
quickly achieve hyperglycemia. The GIR is therefore dic-
tated by the physiological response (i.e., blood glucose).
The initial GIR is lower in FVB/N and DBA/2 mice com-
pared with 129X1/Sv and C57BL/6 mice based on these
glycemic responses (Fig. 4B). When an initial GIR similar
to that in 129X1/Sv and C57BL/6 mice was used in FVB/N
and DBA/2 mice, severe hyperglycemia occurred, often
exceeding the upper limit of detection (27 mmol/l).
The failure of FVB/N mice to respond to glucose in vivo
under clamp conditions is interesting in light of the intact
in vitro response. Catecholamines were elevated in FVB/N
mice compared with other strains and might explain the
failure to increase insulin secretion in vivo (28). The
robust insulin response in vivo in C57BL/6 mice contrasts
with blunted secretion in vitro and previous work showing
that C57BL/6 mice secrete less insulin in vivo compared
with other strains (15,19,22,23). In previous studies, this
has been associated with deletion of the nicotinamide
nucleotide transhydrogenase gene in C57BL/6 mice
(22,29). It is possible that there is long-term compensation
for impaired insulin secretion in C57BL/6 mice (30). How-
ever, there were no profound differences in C57BL/6
pancreatic insulin content, islet insulin content, or -cell
mass.
The correlation coefﬁcient between in vitro and in vivo
insulin secretion in response to hyperglycemia was low
(r  0.20). Insulin content in the total pancreas and
individual islets normalized for size (islet equivalent) was
assessed to understand the mechanism for differences in
insulin secretion in vivo and in isolated islets. There was
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DIABETES, VOL. 57, JULY 2008 1797no systematic relationship between insulin content in
isolated islets and insulin response (insulin secretion
AUC) to high glucose in isolated islets (r  0.25) or the
insulin response to hyperglycemia in vivo (r  0.01). There
was also no relationship between pancreatic insulin con-
tent and insulin response to high glucose in isolated islets
(r  0.39) or in vivo (r  0.17). This suggests that
differences in secretion in isolated islet versus in vivo
studies are due to differences in glucose sensing or stim-
ulus/response coupling. These results highlight that un-
known factors both intrinsic and extrinsic to islets
contribute to these strain-dependent differences in insulin
secretion and may complicate the interpretation of insulin
secretion in vivo and in isolated islets.
An important observation is the strain-dependent differ-
ences in the ratio of whole-blood glucose to plasma
glucose. This is an important consideration because clamp
blood glucose may differ depending on whether whole-
blood or plasma glucose is used. Also, using whole-blood
glucose and plasma [3-
3H]glucose concentrations to calcu-
late glucose speciﬁc activity will underestimate endoRa.I t
is therefore important to use plasma glucose when calcu-
lating glucose turnover regardless of which method was
used to clamp the mouse.
In summary, these results expose differences in glucose
homeostasis in four commonly used mouse strains. Previ-
ous studies have documented the need to consider the
contribution of the inbred strain to results from genetic
manipulation on phenotype. Our results provide an impor-
tant empirical reference for this under carefully controlled
glycemic conditions. Our observations indicate that these
four inbred mouse strains have unique underlying pheno-
types in the basal condition and in response to clamp
conditions. Because C57BL/6 mice are a common back-
ground strain used to study glucose metabolism, it is
important to note that this strain has an intermediate
physiological response to each of the three clamp experi-
ments in comparison with 129X1/Sv, FVB/N, and DBA/2
mice. This is reassuring and suggests that C57BL/6 mice
are a suitable model for studies of glucose homeostasis.
Overall, these results demonstrate that it is critical to
recognize the underlying phenotype of the inbred strain
when performing metabolic testing on genetically mod-
iﬁed mice and when comparing results within and be-
tween laboratories. These data are informative for
selection of background strain, experimental design, and
data interpretation.
ACKNOWLEDGMENTS
These studies were supported by the National Institutes of
Health (NIH) (grants DK-50277, DK-54902, DK-63439, DK-
66636, DK-68764, and DK-69603), the Juvenile Diabetes
Research Foundation International, a Merit Review Award
from the VA Research Service, the Vanderbilt Mouse
Metabolic Phenotyping Center (Grant DK-59637), and the
Vanderbilt Diabetes Research and Training Center (Grant
DK-20593).
We thank the members of the NIH Mouse Metabolic
Phenotyping Center Consortium (University of Cincinnati,
University of Texas Southwestern, University of Washing-
ton [Seattle], Case Western Reserve University, Medical
College of Georgia, and Yale University) and its executive
committee for their helpful input during the course of
these studies. We thank Marcela Brissova for help prepar-
ing the manuscript. We also thank Eric Allen, Angela
Slater, Bakula Trevedi, and Wanda Snead of the Vanderbilt
MMPC Hormone and Analytical Assays Core for perform-
ing hormone assays.
REFERENCES
1. Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA: Effects
of increased glucokinase gene copy number on glucose homeostasis and
hepatic glucose metabolism. J Biol Chem 272:22570–22575, 1997
2. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH: Considerations in
the design of hyperinsulinemic-euglycemic clamps in the conscious
mouse. Diabetes 55:390–397, 2006
3. Coleman DL: The inﬂuence of genetic background on the expression of
mutations at the diabetes (db) locus in the mouse. VI: Hepatic malic
enzyme activity is associated with diabetes severity. Metabolism 41:1134–
1136, 1992
4. Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B,
Dietz KR, Le Roith D, Reitman ML: Genetic background (C57BL/6J versus
FVB/N) strongly inﬂuences the severity of diabetes and insulin resistance
in ob/ob mice. Endocrinology 145:3258–3264, 2004
5. Kulkarni RN, Almind K, Goren HJ, Winnay JN, Ueki K, Okada T, Kahn CR:
Impact of genetic background on development of hyperinsulinemia and
diabetes in insulin receptor/insulin receptor substrate-1 double heterozy-
gous mice. Diabetes 52:1528–1534, 2003
6. Fueger PT, Hess HS, Bracy DP, Pencek RR, Posey KA, Charron MJ,
Wasserman DH: Regulation of insulin-stimulated muscle glucose uptake in
the conscious mouse: role of glucose transport is dependent on glucose
phosphorylation capacity. Endocrinology 145:4912–4916, 2004
7. Brissova M, Nicholson WE, Shiota M, Powers AC: Assessment of insulin
secretion in the mouse. Methods Mol Med 83:23–45, 2003
8. Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW,
Wright CV, Powers AC: Reduction in pancreatic transcription factor PDX-1
impairs glucose-stimulated insulin secretion. J Biol Chem 277:11225–
11232, 2002
9. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, Chen
Z, Carr C, Jerome WG, Chen J, Baldwin HS, Nicholson W, Bader DM, Jetton
T, Gannon M, Powers AC: Pancreatic islet production of vascular endo-
thelial growth factor-a is essential for islet vascularization, revasculariza-
tion, and function. Diabetes 55:2974–2985, 2006
10. Morgan CR, Lazarow A: Immunoassay of insulin using a two-antibody
system. Proc Soc Exp Biol Med 110:29–32, 1962
11. Macdonald IA, Lake DM: An improved technique for extracting cat-
echolamines from body ﬂuids. J Neurosci Methods 13:239–248, 1985
12. Jacobson L, Ansari T, Potts J, McGuinness OP: Glucocorticoid-deﬁcient
corticotropin-releasing hormone knockout mice maintain glucose require-
ments but not autonomic responses during repeated hypoglycemia. Am J
Physiol Endocrinol Metab 291:E15–E22, 2006
13. Altszuler N, De Bodo RC, Steele R, Wall JS: Measurement of size and
turnover rate of body glucose pool by the isotope dilution method. Am J
Physiol 187:15–24, 1956
14. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ:
Quantitative insulin sensitivity check index: a simple, accurate method for
assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–
2410, 2000
15. Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, Hull
RL, Kahn SE, Proietto J: Differential effect of inbred mouse strain
(C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a
high fat diet. J Endocrinol 187:45–53, 2005
16. Bock T, Pakkenberg B, Buschard K: Genetic background determines the
size and structure of the endocrine pancreas. Diabetes 54:133–137, 2005
17. Burgess SC, Jeffrey FM, Storey C, Milde A, Hausler N, Merritt ME, Mulder
H, Holm C, Sherry AD, Malloy CR: Effect of murine strain on metabolic
pathways of glucose production after brief or prolonged fasting. Am J
Physiol Endocrinol Metab 289:E53–E61, 2005
18. Funkat A, Massa CM, Jovanovska V, Proietto J, Andrikopoulos S: Meta-
bolic adaptations of three inbred strains of mice (C57BL/6, DBA/2, and
129T2) in response to a high-fat diet. J Nutr 134:3264–3269, 2004
19. Goren HJ, Kulkarni RN, Kahn CR: Glucose homeostasis and tissue
transcript content of insulin signaling intermediates in four inbred strains
of mice: C57BL/6, C57BLKS/6, DBA/2, and 129X1. Endocrinology 145:3307–
3323, 2004
20. Kooptiwut S, Zraika S, Thorburn AW, Dunlop ME, Darwiche R, Kay TW,
Proietto J, Andrikopoulos S: Comparison of insulin secretory function in
INBRED MOUSE STRAIN GLUCOSE METABOLISM IN VIVO
1798 DIABETES, VOL. 57, JULY 2008two mouse models with different susceptibility to beta-cell failure. Endo-
crinology 143:2085–2092, 2002
21. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp
JJ: Genetic variation among 129 substrains and its importance for targeted
mutagenesis in mice. Nat Genet 16:19–27, 1997
22. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V,
Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft
FM, Cox RD: A genetic and physiological study of impaired glucose
homeostasis control in C57BL/6J mice. Diabetologia 48:675–686, 2005
23. Zraika S, Aston-Mourney K, Laybutt DR, Kebede M, Dunlop ME, Proietto J,
Andrikopoulos S: The inﬂuence of genetic background on the induction of
oxidative stress and impaired insulin secretion in mouse islets. Diabeto-
logia 49:1254–1263, 2006
24. Choi CS, Fillmore JJ, Kim JK, Liu ZX, Kim S, Collier EF, Kulkarni A,
Distefano A, Hwang YJ, Kahn M, Chen Y, Yu C, Moore IK, Reznick RM,
Higashimori T, Shulman GI: Overexpression of uncoupling protein 3 in
skeletal muscle protects against fat-induced insulin resistance. J Clin
Invest 117:1995–2003, 2007
25. Handschin C, Choi CS, Chin S, Kim S, Kawamori D, Kurpad AJ, Neubauer
N, Hu J, Mootha VK, Kim YB, Kulkarni RN, Shulman GI, Spiegelman BM:
Abnormal glucose homeostasis in skeletal muscle-speciﬁc PGC-1alpha
knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk.
J Clin Invest 117:3463–3474, 2007
26. Zhang D, Liu ZX, Choi CS, Tian L, Kibbey R, Dong J, Cline GW, Wood PA,
Shulman GI: Mitochondrial dysfunction due to long-chain Acyl-CoA dehy-
drogenase deﬁciency causes hepatic steatosis and hepatic insulin resis-
tance. Proc Natl Acad SciUSA104:17075–17080, 2007
27. Jacobson L, Ansari T, McGuinness OP: Counterregulatory deﬁcits occur
within 24 h of a single hypoglycemic episode in conscious, unrestrained,
chronically cannulated mice. Am J Physiol Endocrinol Metab 290:E678–
E684, 2006
28. Porte D Jr, Williams RH: Inhibition of insulin release by norepinephrine in
man. Science 152:1248–1250, 1966
29. Aston-Mourney K, Wong N, Kebede M, Zraika S, Balmer L, McMahon JM,
Fam BC, Favaloro J, Proietto J, Morahan G, Andrikopoulos S: Increased
nicotinamide nucleotide transhydrogenase levels predispose to insulin
hypersecretion in a mouse strain susceptible to diabetes. Diabetologia
50:2476–2485, 2007
30. Clee SM, Attie AD: The genetic landscape of type 2 diabetes in mice.
Endocr Rev 28:48–83, 2007
E.D. BERGLUND AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1799